Tianjin Pharmaceutical da Ren Tang Group Ltd 2018 AR2
The report outlines Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's financial and operational performance for the fiscal year 2018, highlighting a 12% increase in revenue to approximately RMB 6,359 million. It details the company's corporate governance practices, technological innovations, and strategic marketing models that drove sales growth, such as Suxiao Jiuxin Wan exceeding RMB 1 billion in sales. Additionally, the report includes a brief sustainability section addressing key economic, environmental, and social topics, noting that the full 2018 Sustainability Report would be published in May 2019.
Company: Tianjin Pharmaceutical da Ren Tang Group Ltd
Sector: Manufacturing
Country: China
Year: 2018
Type: AR2
Pages: 172
Back to company
Tianjin Pharmaceutical da Ren Tang Group Ltd
Annual Report
The report outlines Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's financial and operational performance for the fiscal year 2018, highlighting a 12% increase in revenue to approximately RMB 6,359 million. It details the company's corporate governance practices, technological innovations, and strategic marketing models that drove sales growth, such as Suxiao Jiuxin Wan exceeding RMB 1 billion in sales. Additionally, the report includes a brief sustainability section addressing key economic, environmental, and social topics, noting that the full 2018 Sustainability Report would be published in May 2019.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2018 - Dec 31, 2018
Fiscal Year
2018
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
No data available